The challenges posed in the treatment of Helicobacter pylori are increasing: falling rates of eradication and the rising prevalence of antibiotic-resistant H. pylori strains have led to a decline in ...
A retrospective study of the efficacy and safety of donafenib combined with TACE as adjuvant therapy in patients with high-risk recurrence factors after hepatocellular carcinoma surgery. This is an ...
Expert Rev Anticancer Ther. 2012;12(12):1545-1547. Many other clinical trials aimed at optimizing sequential therapy in mRCC are currently ongoing and their results are eagerly awaited in order to ...
Combinatorial targeted therapies are more effective in treating cancer by blocking by-pass mechanisms or inducing synthetic lethality. However, their clinical application is hampered by resistance and ...
Recent research results from the Max-Planck-Institute for Evolutionary Biology in Plön (MPI) suggest that rapid switching of antibiotics during the treatment of a patient could successfully counteract ...
Hanging in the Balance: Making Decisions About the Benefits and Harms of Breast Cancer Screening Among the Oldest Old Without a Safety Net of Scientific Evidence To take advantage of the activity of ...
Michael Wang, MD, highlights several notable abstracts from ASH 2025 that collectively underscore continued progress in ...
Advanced melanoma is one of the deadliest types of cancer, with a 5-year survival rate of only 27% for patients with distant metastases. Recent advances in targeted therapies and immunotherapies have ...
Table 2. Modality of response/resistance to first-line VEGF/VEGFR inhibitors and possible second-line treatment options to be explored. Clinical response to first-line therapy Putative molecular ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback